Huili Biology completed round A financing and added synthetic biology track

Recently, a new generation of synthetic biology enzyme computing design platform - Huili Biotech announced the completion of nearly 3 million yuan of Series A financing, jointly led by Legend Capital and Boyuan Capital, followed by Qianji Capital, Yunqi Capital and Zhongwei Capital, and Taihe Capital served as financial advisors. This round of financing will be used to accelerate the construction and operation of large-scale production facilities, the R&D of new product pipelines, and the expansion of talent teams.

Synthesis and Application of Pyrazine Carboxylic Acid - Research and Development Department: Wei Yongming

As an important pharmaceutical intermediate, pyrazinecarboxylic acid is widely used in the hypoglycemic drug glipizide and a new generation of long-acting hypolipidemic drug aximus, and its derivative methyl pyrazinecarboxylate is also an important drug for the treatment of tuberculosis. There are 3 main synthesis methods: 1. Chemical synthesis method: there are mainly 3 ways: 1) Potassium permanganate is used in the preparation of oxidation, chlorination, hydrolysis and re-oxidation, which has large pollution, poor product traits, and the yield is less than 20%. 2) Prepared by chlorination, acylation, hydrolysis and oxidation, the yield is less than 50%.

Huili Biology and Novozymes China have reached strategic cooperation to jointly promote the development of AI enabled neoplasm enzyme catalytic technology

Recently, Jiangsu Huili Biotechnology Co., Ltd. (hereinafter referred to as "Huili Biotechnology") and Novozymes (China) Investment Co., Ltd. (hereinafter referred to as "Novozymes China") officially signed a strategic cooperation agreement to form a long-term strategic partnership in the fields of industrial biocatalysis, pharmaceutical intermediates and APIs. At the ceremony, Mr. Ye Yang, CEO of Huili Biologics, and Mr. Ye Xiaofeng, Vice President of Agriculture and Industry of Novozymes China, signed the contract on behalf of both parties.

Exclusive interview with Huili Biotechnology, a cutting-edge synthetic biology team, building a computing platform for implementing enzyme scenario design in China, enabling rational design and modification of enzymes. The industrialization of multiple pro

Enzymes are ubiquitous catalysts in living organisms, which can efficiently and selectively catalyze various biochemical reactions under mild conditions, and subtly regulate extremely complex metabolic processes in living organisms. In the process of natural enzyme application to industrial catalytic technology, a lot of excavation, screening, design improvement and other work are required. In recent years, the design ideas of synthetic biology engineering and the emergence of a large number of new

Jiangsu Huili Biotechnology Co., Ltd. Annual Production of 200 tons of Acimox and 1000 tons of Flufenicol API Project Environmental Impact Assessment First Announcement

According to the requirements of the Law of the People's Republic of China on Environmental Impact Assessment and the Regulations on the Management of Environmental Protection of Construction Projects, Jiangsu Huili Biotechnology Co., Ltd. must carry out environmental impact assessment for the annual output of 200 tons of axilimus and 1000,4 tons of florfenicol API projects. In accordance with the requirements of the Measures for Public Participation in Environmental Impact Assessment (Order No. 200 of the Ministry of Ecology and Environment), the first announcement of the environmental impact assessment of the project is made, the relevant information of the environmental assessment of the project is disclosed, and public opinions are widely solicited. The relevant announcement is as follows: I. Project Overview Project Name: Annual output of 1000 tons of aximus and 3 tons of florfenicol API

Beauty research: Seaweed sugar in honey can reduce arteriosclerosis

Research at the University of Washington in the United States has shown that trehalose, the natural sugar in honey, can reduce arteriosclerosis and prevent heart disease.

The study was published in the British journal Nature Communications.

The researchers divided mice suffering from arteriosclerosis into four groups, injecting trehalose, injecting other sugars, oral trehalose, and no treatment.

It was found that the intravascular plaques of the trehalose-injected mice had a diameter of 0.25 mm, while the intravascular plaques of the untreated mice had a diameter of 0.35 mm.

Warm congratulations on the opening of this website

Warm congratulations on the opening of this website